Cambridge, MA (PRWEB) October 6, 2009
Leading health and technology experts gathered recently at the Massachusetts Institute of Technology's Faculty Club for The Future of Health Technology Summit™ to explore advanced medical technologies being used to save lives, reduce suffering and extend human potential. Among the featured presentations was "Artificial Heart--Past, Current and Future," by Alexander Medvedev, PhD., Vice President, Research & Development, Terumo Heart, who described the innovation behind the DuraHeart™ Left-Ventricular Assist System (LVAS), a next-generation medical device designed to help sustain at-risk patients awaiting heart transplant.
The DuraHeart LVAS is the first, third-generation rotary blood pump designed for long-term patient support that incorporates a centrifugal flow rotary pump with an active magnetically levitated impeller featuring three position sensors and magnetic coils that optimize blood flow, while minimizing device wear and tear. The DuraHeart LVAS is currently being studied in the DuraHeart Pivotal U.S. Trial for Bridge-to-Transplant, a multi-center, prospective, non-randomized study, involving 140 patients in up to 40 centers nationwide. The study will evaluate the safety and efficacy of the device in helping to sustain patients awaiting heart transplant who are at risk of death due to end-stage left ventricular failure. The DuraHeart LVAS carries a CE Mark and is currently available for sale in European countries.
"I am grateful for the opportunity to present at The Future of Health Technology Summit and share the genesis of our DuraHeart program, which is the latest in life-saving LVAS technology and has been used to treat more than 100 patients globally to date," said Dr. Medvedev. "From our new award-winning manufacturing facility to our exciting, global clinical program, to a robust data set representing more than 78 patient years, attendees learned how we are bringing this technology to market from the ground up."
The Future of Health Technology Summit has been organized by The Future of Health Technology Institute since 1996 and focuses on key technologies and challenges to the future of global health care to enhance health and lives. The Institute's goals are to bring together high level thinkers in the area of emerging technology and health to define the health technology agenda for the 21st Century as well as to provide state-of-the art technology training for healthcare professionals and consumers to assure that their voice is included in defining the future of health technology.
"The future of health technology is not unlike the early days of computers or cable television. We have great products, with more being developed at an amazing pace, but we need compatibility and to get more people connected," said Renata Bushko, director of the Future of Health Technology Institute. "Terumo Heart and the DuraHeart device are great examples of how companies are using global resources to develop innovative technology to fight devastating diseases such as heart failure."
About The Future Of Health Technology Institute
The Future of Health Technology Institute in Hopkinton, Mass., is the health technology think tank dedicated to defining the health technology agenda for the 21st century. The institute was established to identify the most promising technologies to improve the quality of health care and to define promising health technology research areas needed to meet future health challenges. Renata Bushko (Bushko@fhti.org) has chaired annual Future of Health Technology summits since founding the institute in 1996. These summits engage creative minds from the technology and healthcare fields in envisioning the future of technology for global healthcare. For further information, visit the Web site at http://www.fhti.org.
About Terumo Heart, Inc.
Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe. For more information visit http://www.terumoheart.com.